Eloralintide

• Discovery and translational work reported selective human AMY1R activation, favorable rat and monkey pharmacokinetics, reduced food intake and body weight in obese rats, and less conditioned taste avoidance than cagrilintide in rats. ADA 2025 abstract 849-P was a conference precursor to the later peer-reviewed discovery report, not an independent human trial.
• In the published single-ascending-dose Phase 1 portion of NCT05295940, 48 healthy participants received 0.04 to 12 mg once. At Day 29, mean body-weight change was -2.5% with 4 mg and -4.4% with 12 mg versus +0.6% with placebo; the small cohorts were designed primarily for safety and pharmacokinetics, not definitive efficacy.
• In the published multiple-dose Phase 1 portion of NCT05295940, 100 adults with overweight or obesity received weekly eloralintide or placebo for 12 weeks. At Week 12, placebo-adjusted least-squares mean body-weight reduction was 2.6% at 1.2 mg, 8.9% at 3 mg, 8.5% at 6 mg, and 11.3% at 12 mg; the placebo group itself gained 0.2%.
• The 48-week randomized Phase 2 trial NCT06230523 enrolled 263 adults with obesity or overweight and a weight-related comorbidity, without type 2 diabetes. Mean body-weight changes under the efficacy estimand were -9.5%, -12.4%, -17.6%, -20.1%, -19.9%, and -16.4% for 1, 3, 6, 9, 6-to-9, and 3-to-6-to-9 mg regimens, respectively, versus -0.4% with placebo.
• Phase 2 also reported a maximum mean absolute loss of 21.3 kg, a maximum mean waist reduction of 17.1 cm, no clear weight plateau at Week 48, and partial regain during the 10-week off-treatment follow-up. A DXA subset showed roughly three parts fat mass to one part lean mass lost, not proven preservation of human muscle.
• Exploratory Phase 2 measures including glucose, insulin, blood pressure, lipids, hsCRP, and physical function improved in some arms. These analyses do not establish treatment for diabetes, inflammation, or cardiovascular events. No multiplicity adjustment was performed for reported p values, so they should be interpreted as exploratory despite the large weight-loss estimates.
• The Phase 2 population was 78% female and 78% White, and each active arm was modest in size. The study establishes a strong efficacy signal, not complete evidence across sexes, races, diabetes status, comorbidities, pregnancy, or long-term use.
• An accepted EASD 2026 Phase 1b abstract covered NCT06345066 and the Japanese NCT06297616 combination cohorts. In Study A, mean weight change at Week 16 was -10.0% with tirzepatide 5 mg and -17.0%, -18.2%, or -20.5% with eloralintide 3, 6, or 9 mg plus tirzepatide 5 mg. At Week 32, tirzepatide 15 mg produced -17.8%, compared with -23.6% or -29.0% for eloralintide 9 mg plus tirzepatide 15 mg, depending on the eloralintide starting dose.
• In Japanese Study B at Week 24, mean weight change was -0.5% with double placebo, -16.4% with tirzepatide 15 mg, -14.2% with eloralintide 9 mg, and -25.5% with the combination.
• Those combination findings are from a Lilly-supported abstract accepted for presentation on September 30, 2026; as of this review, it had not yet been presented or published as a peer-reviewed full paper. All authors were Lilly employees. Endpoint samples were small and incomplete in several arms: the -29.0% arm had valid observations for 3 of 12 randomized participants. Combination arms had more treatment-emergent adverse events; gastrointestinal events were most common and were mostly mild or moderate.
• An August 1, 2026 registry audit found six completed direct studies: NCT05295940, NCT06230523, NCT06297616, NCT06345066, NCT06916065, and NCT06916091. Only the first two currently have peer-reviewed eloralintide outcome papers identified in this review; NCT06297616 and NCT06345066 additionally have the accepted EASD combination abstract. Only NCT06230523 had posted ClinicalTrials.gov results.
• NCT06603571, a Phase 2 monotherapy/tirzepatide study in type 2 diabetes, was active but not recruiting. Recruiting Phase 2 studies evaluate eloralintide with macupatide, while Phase 1 studies address formulations, metabolic effects, and hepatic or renal impairment.
• Five Phase 3 records were recruiting: ENLIGHTEN-1 without diabetes, ENLIGHTEN-2 with type 2 diabetes, ENLIGHTEN-3 in obstructive sleep apnea, ENLIGHTEN-4 in knee-osteoarthritis pain, and ENLIGHTEN-6 as an add-on to stable weekly incretin therapy. These records describe planned endpoints and cannot be counted as positive results.
• NCT07738614, first posted July 31, 2026, is a not-yet-recruiting Phase 1 multiple-dose study in an estimated 56 adults with obesity or overweight. Four masked subcutaneous eloralintide cohorts and placebo use oral acetaminophen as a gastric-emptying probe; acetaminophen pharmacokinetic endpoints are measured through Day 65 and eloralintide pharmacokinetics through Day 106. Participation is expected to last about 21 weeks. Numeric eloralintide doses are not public.
• The registered program contained 19 direct eloralintide records plus the NCT06143956 parent master protocol, 20 records total, at the audit date. Trial status, enrollment, and completion dates can change, so registry records should be rechecked before making current-development claims.
• A 2026 network meta-analysis and two recent reviews place eloralintide among emerging long-acting amylin therapies. The meta-analysis included only six heterogeneous trials and rated most comparisons low or very low certainty; these secondary sources do not replace direct trials or support definitive head-to-head claims.
• A 2026 sponsor poster in diet-induced-obesity rats reported about 20% body-weight reduction after four weeks of tirzepatide 30 nmol/kg plus eloralintide 100 nmol/kg subcutaneously every three days. Adding eloralintide after two weeks of tirzepatide produced about 21% reduction; either drug alone produced about 9% to 10%. These nonhuman doses do not establish a human combination protocol.

The entries below separate clinical, preclinical, and community-reported contexts. They are reference material, not personalized dosing instructions. Eloralintide has no FDA-approved dose.

• Protocol 1: Phase 1 single-ascending-dose research [Clinical/Human Trial]; Route: Subcutaneous (SC); Dose: one dose of 0.04, 0.12, 0.4, 1.2, 4, or 12 mg; Frequency: Single administration; Follow-up: body-weight and pharmacokinetic analysis through Day 29, with safety follow-up through Day 60; Status: Investigational and not FDA-approved.
• Protocol 2: Phase 1 multiple-dose research without escalation [Clinical/Human Trial]; Route: Subcutaneous (SC); Dose: 1.2, 3, 6, or 12 mg; Frequency: Once weekly; Duration: 12 weeks of treatment plus 10 weeks of post-treatment follow-up; Titration/loading: none in the published cohorts; Status: Investigational and not FDA-approved.
• Protocol 3: Phase 2 obesity research [Clinical/Human Trial]; Route: Subcutaneous (SC); Dose: fixed 1, 3, 6, or 9 mg weekly for 48 weeks; or 6 mg for 20 weeks then 9 mg for 28 weeks; or 3 mg for 4 weeks, 6 mg for 4 weeks, then 9 mg for 40 weeks; Status: Investigational and not FDA-approved.
• Protocol 4: Phase 1b eloralintide plus tirzepatide combination research [Clinical/Human Trial]; Evidence: Accepted EASD 2026 conference abstract; Route: Subcutaneous (SC); Frequency: Once weekly; Study A at 16 weeks: placebo plus tirzepatide 5 mg, or eloralintide 3, 6, or 9 mg plus tirzepatide 5 mg; tirzepatide started at 2.5 mg; Study A at 32 weeks: placebo plus tirzepatide 15 mg, or eloralintide 9 mg starting at 1.5 or 3 mg plus tirzepatide 15 mg; tirzepatide started at 2.5 mg; Japanese Study B at 24 weeks: double placebo; placebo plus tirzepatide 15 mg; eloralintide 9 mg plus placebo; or eloralintide 9 mg plus tirzepatide 15 mg; eloralintide started at 3 mg and tirzepatide at 2.5 mg; Titration/loading: The abstract explicitly describes four-week escalation for the arm targeting eloralintide 9 mg from a 3 mg start plus tirzepatide 15 mg from a 2.5 mg start; intermediate steps were not disclosed; Status: Investigational, accepted-abstract evidence, and not FDA-approved.
• Protocol 5: eloralintide plus tirzepatide diet-induced-obesity rat experiments [Animal/Preclinical - not a human protocol]; Route: Subcutaneous (SC); Co-administration: eloralintide 100 nmol/kg plus tirzepatide 30 nmol/kg every three days for four weeks; Adjunctive: tirzepatide 30 nmol/kg every three days for two weeks, then add eloralintide 1, 10, or 100 nmol/kg every three days for two more weeks; Status: Nonhuman sponsor experiment only, not a human-equivalent dose or stacking protocol.
• Protocol 6: Early gray-market report pattern [Community/Anecdotal - unverified]; Claimed route: Injection, usually described as subcutaneous; Claimed starting amount: 0.5 mg to 1 mg per administration among a small set of users; Frequency: Once weekly or every four to five days; Follow-up: Usually days to several weeks; Context: Most combined eloralintide with tirzepatide and/or retatrutide and often changed those doses; Status: Sparse, short-term self-report; not approved or clinically validated and does not establish a safe dosing protocol.
• Several later Phase 1, Phase 2, and Phase 3 records omit numeric dose levels or use masked labels such as Dose 1 through Dose 4. Do not infer a Phase 3 or eventual label dose from older Phase 1 or Phase 2 arms.
• The August 1, 2026 anecdotal audit found only 10 unique Reddit handles claiming gray-market use, and claimed dose histories sometimes conflicted. Handles are not verified people, follow-up was short, and likely account overlap could not be excluded.
• One poster claimed 1 mg daily for four days and later described even larger doses. That extreme outlier is excluded from the reported pattern: published eloralintide studies use weekly dosing, and its approximately two-week half-life makes closely repeated dosing an accumulation concern, not evidence of a valid daily protocol.
• Retrospective posts by purported former trial participants sometimes recalled fixed 9 mg weekly or 6-to-9 mg schedules. Those memories are unverified and do not validate gray-market products, starting doses, or titration.
• Human evidence is for sponsor-manufactured subcutaneous study drug. Oral, nasal, buccal, topical, and transdermal eloralintide routes were not supported by the direct human studies found.

• After single subcutaneous doses, median time to maximum concentration was 72.0 to 132.2 hours, showing unusually slow absorption.
• Terminal geometric-mean half-life was 310 to 366 hours, or approximately 12.9 to 15.3 days, across the 0.4 to 12 mg single-dose range.
• A simple four-to-five-half-life estimate places near-steady exposure at roughly 7 to 11 weeks. The multiple-dose study assessed steady-state exposure on Day 78; this describes accumulation, not when weight loss is complete.
• At Week 12, steady-state AUC and maximum concentration were approximately dose proportional from 1.2 to 12 mg. Reported peak-to-trough ratios of about 1.28 to 1.38 reflect relatively flat weekly exposure.
• The half-life is longer than the weekly dosing interval used in trials, so exposure accumulates and dose changes or adverse effects may take weeks to show their full trajectory. Washout is also prolonged.
• Community claims of effects emerging two to five days after injection and increasing over successive weeks are pharmacokinetically plausible given the slow absorption and accumulation. They remain unverified and heavily confounded.
• Dedicated hepatic-impairment and renal-impairment studies were still recruiting at the audit date. No evidence-based dose adjustment can be inferred before those results and eventual labeling are available.
• Weekly trial administration reflects the molecule's design. It is not evidence that unverified vials, concentrations, reconstitution practices, or schedules are equivalent to the clinical product.

• An accepted EASD 2026 abstract provides preliminary human weight and tolerability results for once-weekly eloralintide plus tirzepatide in NCT06345066 and the Japanese combination portion of NCT06297616. It was Lilly-supported, had not yet been presented as of this review, is not a peer-reviewed full paper, and had very small endpoint samples in several arms.
• Other eloralintide plus tirzepatide records remain in clinical development without posted peer-reviewed efficacy results. The accepted abstract should not be generalized to unreported arms, populations, or long-term outcomes.
• Phase 2 studies are also testing eloralintide with the long-acting GIP-receptor agonist macupatide. Those protocols do not establish a safe off-trial stack.
• ENLIGHTEN-6 is testing eloralintide as an add-on for people with persistent obesity while taking stable weekly incretin therapy. Its existence is evidence of a research question, not proof of benefit or safety.
• Rat data suggest additive weight and fat-mass effects with tirzepatide. Animal co-administration results cannot supply a human dose, titration, interaction profile, or adverse-event rate.
• Most early gray-market self-reports combined eloralintide with tirzepatide and/or retatrutide while changing those doses, so they cannot isolate eloralintide or establish a safe stack.
• Combining eloralintide with GLP-1, GIP/GLP-1, glucagon, amylin, or other appetite-suppressing agents outside a trial may compound nausea, inadequate intake, dehydration, gallbladder risk, and excessive weight loss. No approved combination instructions exist.
• The early gastric-emptying study used acetaminophen as a probe and was limited; NCT07738614 is designed to investigate this question further. Effects on other oral drugs, insulin or secretagogue requirements, contraceptive exposure, and peri-procedural aspiration risk remain unknown for eloralintide, and current concerns are extrapolated from related drug classes.
• Because there is no approved label, interaction claims should remain “unknown” unless a direct eloralintide study supports them.

• There is no FDA-approved label, so eloralintide has no formal product contraindication list. Trial exclusions are safety guardrails for research and should not be rewritten as established contraindications.
• In the 48-person single-dose study, 9 of 36 eloralintide recipients reported adverse events; 15 of 16 events were mild. Two participants had gastrointestinal events, including one moderate vomiting event, and no serious adverse event or discontinuation occurred.
• In the 100-person 12-week study, common eloralintide adverse events included decreased appetite (19%), headache (12%), fatigue (11%), diarrhea (10%), nausea (8%), and vomiting (4%). Most were mild, but the small study does not define long-term risk.
• That multiple-dose study recorded mood-related events in four participants; all three affected participants in the 12 mg cohorts stopped treatment, and events resolved within days. This is a signal to monitor, not proof of a causal psychiatric syndrome.
• Mean pulse fell with treatment and was 14.4 beats/min below baseline in the 12 mg group at Week 12; no symptomatic bradycardia was reported. The Phase 2 trial excluded people with ongoing or prior bradyarrhythmia or sinus bradycardia.
• One acute-kidney-injury serious adverse event in the 6 mg Phase 1 cohort was judged unrelated by the investigator. No deaths occurred in the published Phase 1 multiple-dose study.
• In Phase 2, any adverse event occurred in 81% of pooled active participants versus 71% with placebo; serious events occurred in 5% versus 6%, and discontinuation for adverse events in 10% versus 8%. No serious event was judged treatment-related.
• Pooled Phase 2 rates versus placebo were nausea 33% versus 13%, fatigue 27% versus 12%, diarrhea 15% versus 10%, constipation 15% versus 6%, vomiting 8% versus 0%, decreased appetite 10% versus 4%, and alopecia 7% versus 0%. The 3-to-6-to-9 mg escalation arm generally had lower gastrointestinal rates than some non-titrated higher-dose arms.
• In the accepted EASD 2026 Phase 1b combination abstract, combination arms had more treatment-emergent adverse events than comparator arms; gastrointestinal events were most common and were mostly mild or moderate. The abstract and small endpoint samples do not define a reliable long-term combination adverse-event rate.
• Phase 2 reported one discontinuation due to asymptomatic bradycardia in the 6 mg group. Separately, hypotension, orthostatic hypotension, or syncope occurred in 12 of 208 (6%) pooled eloralintide recipients versus 2 of 52 (4%) placebo recipients.
• No deaths, pancreatitis, or cholecystitis occurred during Phase 2, but the sample and duration cannot exclude uncommon or longer-term risks.
• The Phase 2 protocol excluded or restricted several higher-risk contexts, including previous pancreatitis, bradyarrhythmia, recent major cardiovascular events, symptomatic gallbladder disease, poorly controlled hypertension, and a lifetime suicide-attempt history. Safety outside those selection criteria is less certain.
• Pregnancy, breastfeeding, pediatric use, long-term maintenance, major organ impairment, peri-procedural use, and broad drug interactions remain insufficiently characterized.
• Early gray-market posts repeatedly mention fatigue and headache, with some describing fullness or appetite suppression several days after injection. These are qualitative signals, not incidence estimates or causal proof.
• Public posts by purported trial participants also describe fatigue, constipation, nausea or food aversion, hair shedding, and gallstones after rapid weight loss. Blinding, dose recall, diagnosis, and rapid-weight-loss confounding prevent adding these anecdotes to controlled-trial event rates.
• Gray-market products add risks separate from eloralintide's trial safety profile: wrong identity, incorrect potency, aggregation, contamination, endotoxin, nonsterility, and formulations unlike the sponsor's trial product.

There is no approved eloralintide monitoring schedule. These are the domains measured in trials or made relevant by published signals.

• Track body weight, waist circumference, weight-loss rate, appetite, nutritional adequacy, and body composition where available. Human preservation of lean mass has not yet been established.
• Document nausea, vomiting, diarrhea, constipation, fluid intake, orthostatic symptoms, and renal function when intake or hydration is impaired.
• Track resting pulse, blood pressure, and symptoms such as dizziness, presyncope, or exercise intolerance. ECG evaluation belongs in clinical care when bradyarrhythmia is a concern.
• Monitor mood, fatigue, sleep, anxiety, depressive symptoms, and suicidal thinking rather than dismissing psychiatric changes as ordinary dieting effects.
• Glucose, HbA1c, fasting insulin, lipids, and liver markers are relevant in metabolic studies, especially as the program expands into type 2 diabetes and combination therapy.
• Assess gallbladder or pancreatic symptoms clinically rather than ordering enzymes or imaging as routine self-screening without an indication.
• Record injection-site reactions and possible hypersensitivity or anti-drug-antibody signals in formal research settings.
• Hepatic and renal impairment data are still being collected; normal routine labs cannot establish a safe dose for an unapproved product.

• Eloralintide is investigational and in Phase 3 development. It is not FDA-approved for obesity, diabetes, sleep apnea, osteoarthritis pain, or any other indication as of August 1, 2026.
• There is no FDA-approved branded or commercial drug product, prescribing information, or consumer dose.
• FDA's Global Substance Registration System lists the name, aliases, structure, and UNII 73G3354J8W. The FDA record explicitly notes that a UNII does not imply regulatory review or approval.
• ClinicalTrials.gov identifies some studies as involving a U.S. FDA-regulated drug product. That registry field is not an approval marker.
• Under the 2026 WADA Prohibited List, a pharmacologically active substance without approval for human therapeutic use generally falls under S0 and is prohibited at all times. Tested athletes should verify status with their anti-doping organization before exposure.
• Research-use or vendor availability is not regulatory authorization. Gray-market products are not equivalent to the eloralintide material used in clinical trials.

1. [B] Briere et al. (2025). Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism. 102:102271. PMID:41109426; PMCID:PMC12640043; DOI:10.1016/j.molmet.2025.102271.

2. [C] Bhattachar et al. (2026). Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism. 28(4):2651-2660. PMID:41559929; PMCID:PMC12992164; DOI:10.1111/dom.70439.

3. [A] Billings et al. (2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week Phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 406(10520):2631-2643. PMID:41207310; DOI:10.1016/S0140-6736(25)02155-5.

4. [D] Briere et al. (2026). 3082-LB: The Selective Amylin Analog Eloralintide Enhanced Weight-Loss Efficacy when Combined with Tirzepatide in DIO Rats. Diabetes. 75(Suppl 1):3082-LB. DOI:10.2337/db26-3082-LB.

5. [G] ClinicalTrials.gov. NCT05295940. Phase 1 single- and multiple-dose study of LY3841136 in healthy participants and adults with overweight or obesity.

6. [G] ClinicalTrials.gov. NCT06143956. Phase 2 chronic-weight-management umbrella master protocol; parent record for Eloralintide intervention-specific appendices.

7. [G] ClinicalTrials.gov. NCT06230523. Completed Phase 2 Eloralintide-versus-placebo obesity study with posted results.

8. [G] ClinicalTrials.gov. NCT06297616. Completed Phase 1 Eloralintide monotherapy and tirzepatide-combination study in Japanese participants.

9. [G] ClinicalTrials.gov. NCT06345066. Completed Phase 1 Eloralintide-plus-tirzepatide safety and tolerability study.

10. [G] ClinicalTrials.gov. NCT06603571. Phase 2 Eloralintide and tirzepatide study in adults with obesity or overweight and type 2 diabetes.

11. [G] ClinicalTrials.gov. NCT06916065. Completed Phase 1 Eloralintide bioavailability, monotherapy, and tirzepatide-combination study.

12. [G] ClinicalTrials.gov. NCT06916091. Completed Phase 1 Eloralintide study in Chinese participants with obesity or overweight.

13. [G] ClinicalTrials.gov. NCT07215559. Phase 2 macupatide and Eloralintide monotherapy and combination study in adults with type 2 diabetes.

14. [G] ClinicalTrials.gov. NCT07282600. ENLIGHTEN-2 Phase 3 study in adults with obesity or overweight and type 2 diabetes.

15. [G] ClinicalTrials.gov. NCT07321886. ENLIGHTEN-1 Phase 3 study in adults with obesity or overweight without type 2 diabetes.

16. [G] ClinicalTrials.gov. NCT07353931. ENLIGHTEN-4 Phase 3 study of weight and knee-osteoarthritis pain outcomes.

17. [G] ClinicalTrials.gov. NCT07369011. ENLIGHTEN-3 Phase 3 study in moderate-to-severe obstructive sleep apnea and obesity or overweight.

18. [G] ClinicalTrials.gov. NCT07392190. ENLIGHTEN-6 Phase 3 Eloralintide add-on study in people taking stable weekly incretin therapy.

19. [G] ClinicalTrials.gov. NCT07401862. Phase 1 pharmacokinetic study in participants with hepatic impairment.

20. [G] ClinicalTrials.gov. NCT07426380. Phase 1 pharmacokinetic study in participants with renal impairment or end-stage renal disease.

21. [G] ClinicalTrials.gov. NCT07589608. Phase 2b macupatide and Eloralintide monotherapy and combination study without type 2 diabetes (structured registry phase: Phase 2).

22. [G] ClinicalTrials.gov. NCT07665879. Phase 1 Eloralintide study of insulin sensitivity, metabolism, and body weight.

23. [G] ClinicalTrials.gov. NCT07701083. Phase 1 pharmacokinetic and bioavailability comparison of two Eloralintide formulations.

24. [G] U.S. Food and Drug Administration. Global Substance Registration System record for Eloralintide, UNII 73G3354J8W. UNII assignment does not imply regulatory review or approval.

25. [G] World Anti-Doping Agency. (2025). International Standard: Prohibited List 2026. S0 Non-Approved Substances.

26. [D] Bhattachar SN, Taylor R, Takenouchi K, et al. (2026). Safety, tolerability, pharmacokinetics and pharmacodynamics of eloralintide and tirzepatide co-administered as once-weekly subcutaneous injections. Accepted and publicly posted EASD 2026 abstract, Presentation 76, scheduled September 30, 2026. Use: Lilly-supported Phase 1b combination regimens, weight outcomes, endpoint sample sizes, and adverse-event summary for NCT06345066 and NCT06297616; all authors were Lilly employees, and the abstract had not yet been presented or peer reviewed at the August 1 audit.

27. [D] Briere DA (presenter). (2025). Eloralintide, a Selective Amylin Analog, Improves Insulin Sensitivity in Diet-induced Obese Rats. Poster-262, ObesityWeek 2025; Obesity. 33(S2). DOI:10.1002/oby.70103. Use: official program and title-level evidence only; the accessible program does not provide methods, doses, or numeric results, and the DOI identifies the poster-abstract supplement rather than this individual poster.

28. [D] Ipsen D, Ballarin-Gonzalez B, von Moo E, Secher A, Raun K. (2025). 86-OR: The Amylin Receptor Selective Agonist NN1213 Reduces Food Intake and Body Weight in Rats without Decreasing Calcium Plasma Levels. Diabetes. 74(Suppl 1):86-OR. DOI:10.2337/db25-86-OR. Use: Novo Nordisk-sponsored rat comparator data, independent of Lilly but authored by Novo employees and stockholders; not proof of a human calcium effect.

29. [D] Briere DA, Long K, Bullock B, et al. (2025). 849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide. Diabetes. 74(Suppl 1):849-P. DOI:10.2337/db25-849-P. Use: conference precursor to the peer-reviewed discovery report; not independent human evidence.

30. [G] ClinicalTrials.gov. NCT07738614. Phase 1 randomized, investigator- and participant-blinded, placebo-controlled multiple-dose study of gastric-emptying delay, pharmacokinetics, safety, and tolerability of eloralintide in adults with obesity or overweight. Not yet recruiting; first posted July 31, 2026; accessed August 1, 2026.

31. [F] Kamrul-Hasan ABM, Khalil I, Mahajan K, et al. (2026). Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. Endocrinology, Diabetes & Metabolism. 9(3):e70247. PMID:42175595; PMCID:PMC13240113; DOI:10.1002/edm2.70247. Use: indirect comparative context; most comparisons were low or very low certainty.

32. [F] Bailey CJ, Flatt PR, Conlon JM. (2026). Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides. 196:171480. PMID:41747885; DOI:10.1016/j.peptides.2026.171480. Use: independent narrative review of the long-acting amylin-therapy landscape.

33. [F] Alhazmi A, le Roux CW. (2026). Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials. Diabetes, Obesity and Metabolism. Online ahead of print. PMID:42452898; DOI:10.1111/dom.71074. Use: narrative review current through April 30, 2026; not a substitute for direct eloralintide trials.

34. [H] Reddit r/Eloralintide community thread. (June-July 2026). Eloralintide Starting Dose? Looking for User Experiences. Use: unverified gray-market starting-amount claims, purported trial recollections, and an extreme daily-dosing outlier; not scientific evidence or dosing guidance.

35. [H] Reddit r/Eloralintide community thread. (July 2026). Eloralintide dosing. Use: unverified short-term gray-market dose, timing, accumulation, and combination claims; not scientific evidence or dosing guidance.

36. [H] Reddit r/Eloralintide community thread. (July 2026). Reta and Elora? Use: unverified reports combining eloralintide with tirzepatide and/or retatrutide; simultaneous drug and dose changes prevent attribution.

37. [H] Reddit r/Eloralintide community thread. (July-August 2026). Starting. Use: mixed prospective plans and two very short first-person reports involving 0.5 mg or 1 mg alongside tirzepatide; not scientific evidence or dosing guidance.

38. [H] Reddit r/Eloralintide community thread. (June-July 2026). One year after study update. Use: unverified retrospective claims by purported former trial participants about dose recall, weight change, fatigue, hair shedding, and gallstones after rapid weight loss; not controlled safety evidence.

39. [H] Reddit r/BiohackingU community thread. (July-August 2026). Eloralintide? Any advice. Use: unverified six-week report of 0.5 mg every four to five days and a five-week 1 mg report; both involved concurrent tirzepatide and/or retatrutide, so efficacy and adverse effects cannot be attributed to eloralintide.